Dalteparin Low Molecular Weight Heparin (LMWH) in ovarian cancer: A phase II randomized study

Thrombosis Research

Volumn 130, Issue 6, 2012, Pages 894-900

  Elit, Laurie M ^a,b   Lee, Agnes Y ^c   Parpia, Sameer ^a,b   Swystun, Laura L ^b,d   Liaw, Patricia C ^b,d   Hoskins, Paul ^c   Julian, Denise H ^a,b   Julian, Jim A ^a,b   Levine, Mark N ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Chemotherapy; Dalteparin; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; D DIMER; DALTEPARIN; PLATINUM DERIVATIVE; PROTEIN C; TAXANE DERIVATIVE; THROMBIN ANTITHROMBIN COMPLEX; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD CLOTTING; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CA-125 ANTIGEN; DALTEPARIN; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870246176     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.09.010     Document Type: Article

References (34)

1. A.P. Heintz, F. Odicino, P. Maisonneuve, U. Beller, J.L. Benedet, and W.T. Creasman Carcinoma of the ovary J Epidemiol Biostat 6 1 2001 107 138
2. R.C. Young, L.A. Walton, S.S. Ellenberg, H.D. Homesley, G.D. Wilbanks, and D.G. Decker Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials N Engl J Med 322 15 1990 1021 1027
3. L.R. Zacharski, and A.Y. Lee Heparin as an anticancer therapeutic Expert Opin Investig Drugs 17 7 2008 1029 1037
4. G.F. Nash, D.C. Walsh, and A.K. Kakkar The role of the coagulation system in tumour angiogenesis Lancet Oncol 2 2001 608 613
5. F.R. Rickles, S. Patierno, and P.M. Fernandez Tissue factor, thrombin, and cancer Chest 124 3 Suppl. 2003 58S 68S
6. W. Ruf, J. Disse, T.C. Carneiro-Lobo, N. Yokota, and F. Schaffner Tissue factor and cell signalling in cancer progression and thrombosis J Thromb Haemost 9 Suppl. 1 2011 306 315
7. A. Amirkhosravi, S.A. Mousa, M. Amaya, and J.L. Francis Antimetastatic effect of tinzaparin, a low-molecular-weight heparin J Thromb Haemost 1 9 2003 1972 1976
8. A. Collen, S.M. Smorenburg, E. Peters, F. Lupu, P. Koolwijk, and C. Van Noorden Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro Cancer Res 60 21 2000 6196 6200
9. J. Ichikawa, H.A. Cole, R.A. Magnussen, N.A. Mignemi, M. Butler, and G.E. Holt Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma Cancer 118 9 2012 2494 2506
10. T. Sciumbata, P. Caretto, P. Pirovano, P. Pozzi, P. Cremonesi, and G. Galimberti Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival Invasion Metastasis 16 3 1996 132 143
11. M. Altinbas, H.S. Coskun, O. Er, M. Ozkan, B. Eser, and A. Unal A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer J Thromb Haemost 2 8 2004 1266 1271
12. F. Icli, H. Akbulut, G. Utkan, B. Yalcin, D. Dincol, and A. Isikdogan Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer J Surg Oncol 95 6 2007 507 512
13. C.P. Klerk, S.M. Smorenburg, H.M. Otten, A.W. Lensing, M.H. Prins, and F. Piovella The effect of low molecular weight heparin on survival in patients with advanced malignancy J Clin Oncol 23 10 2005 2130 2135
14. A.Y. Lee, F.R. Rickles, J.A. Julian, M. Gent, R.I. Baker, and C. Bowden Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism J Clin Oncol 23 10 2005 2123 2129
15. K. Sideras, P.L. Schaefer, S.H. Okuno, J.A. Sloan, L. Ketteh, and T.R. Fitch Low-molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial Mayo Clin Proc 81 2006 758 767
16. A.K. Kakkar, M.N. Levine, Z. Kadziola, N.R. Lemoine, V. Low, and H.R. Patel Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol 22 2004 1944 1948
17. A.O. Rodriguez, T. Wun, H. Chew, H. Zhou, D. Harvey, and R.H. White Venous thromboembolism in ovarian cancer Gynecol Oncol 105 3 2007 784 790
18. S. Tateo, L. Mereu, S. Salamano, C. Klersy, M. Barone, and A.C. Spyropoulos Ovarian cancer and venous thromboembolic risk Gynecol Oncol 99 1 2005 119 125
19. G.F. von Tempelhoff, M. Dietrich, F. Niemann, D. Schneider, G. Hommel, and L. Heilmann Blood coagulation and thrombosis in patients with ovarian malignancy Thromb Haemost 77 3 1997 456 461
20. Y. Matsuura, G. Robertson, D.E. Marsden, S.N. Kim, V. Gebski, and N.F. Hacker Thromboembolic complications in patients with clear cell carcinoma of the ovary Gynecol Oncol 104 2 2007 406 410
21. G.J. Rustin Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials J Clin Oncol 21 10 Suppl. 2003 187 193
22. G.J. Rustin, M. Quinn, T. Thigpen, B.A. du, E. Pujade-Lauraine, and A. Jakobsen New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) J Natl Cancer Inst 96 6 2004 487 488
23. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
24. R. Simon, R.E. Wittes, and S.S. Ellenberg Randomized phase II clinical trials Cancer Treat Rep 69 12 1985 1375 1381
25. K.A. Bauer, and J.I. Weitz Laboratory markers of coagulation and fibrinolysis R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman, Hemostasis and Thrombosis: Basic Principles and Clinical Practice 1994 J. B. Lippincott Company Philadelphia, Pennsylvania 1197 1210
26. S.D. Mukherjee, L.L. Swystun, N. Mackman, J.G. Wang, G. Pond, and M.N. Levine Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients Pathophysiol Haemost Thromb 37 2-4 2010 88 97
27. R.S. Kasthuri, M.B. Taubman, and N. Mackman Role of tissue factor in cancer J Clin Oncol 27 29 2009 4834 4838
28. A. Amirkhosravi, T. Meyer, M. Amaya, M. Davila, S.A. Mousa, and T. Robson The role of tissue factor pathway inhibitor in tumor growth and metastasis Semin Thromb Hemost 33 7 2007 643 652
29. P. Hoskins, I. Vergote, A. Cervantes, D. Tu, G. Stuart, and P. Zola Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel J Natl Cancer Inst 102 20 2010 1547 1556
30. A. Maraveyas, J. Waters, R. Roy, D. Propper, D. Fyfe, and F. Lofts Gemitabine with or without prophylactic weight-adjusted dalteparin in patients with adavnced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study) Eur J Cancer Suppl 7 2 2009 362
31. A. Maraveyas, C. Ettelaie, H. Echrish, C. Li, E. Gardiner, and J. Greenman Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion Blood Coagul Fibrinolysis 21 5 2010 452 458
32. D. Bergqvist, U.S. Burmark, P.A. Flordal, J. Frisell, T. Hallbook, and M. Hedberg Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients [see comments] Br J Surg 82 4 1995 496 501
33. G. Agnelli, G. Gussoni, C. Bianchini, M. Verso, M. Mandala, and L. Cavanna Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Lancet Oncol 10 10 2009 943 949
34. A. Amirkhosravi, T. Meyer, J.Y. Chang, M. Amaya, F. Siddiqui, and H. Desai Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma Thromb Haemost 87 6 2002 930 936